Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior

Blood

Volumn 114, Issue 21, 2009, Pages 4696-4702

  Forconi, Francesco ^a   Sozzi, Elisa ^a   Cencini, Emanuele ^a   Zaja, Francesco ^b   Intermesoli, Tamara ^c   Stelitano, Caterina ^d   Rigacci, Luigi ^e   Gherlinzoni, Filippo ^f   Cantaffa, Renato ^g   Baraldi, Anna ^h   Gallamini, Andrea ⁱ   Zaccaria, Alfonso ^j   Pulsoni, Alessandro ^k   Gobbi, Marco ^l   Tassi, Maristella ^a   Raspadori, Donatella ^a   Leoncini, Lorenzo ^a   Rinaldi, Andrea ^m   Sabattini, Elena ⁿ   Bertoni, Francesco ^m   Pileri, Stefano A ⁿ   Lauria, Francesco ^a   more..

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c OSPEDALI RIUNITI   (Italy)

^d Azienda Ospedaliera Reggio Calabria   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f OSPEDALE CA FONCELLO   (Italy)

^g PUGLIESE CIACCIO HOSPITAL   (Italy)

^h C Arrigo Children's Hospital   (Italy)

ⁱ S CROCE E CARLE HOSPITAL   (Italy)

^j SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^k SAPIENZA UNIVERSITY OF ROME   (Italy)

^l UNIVERSITY OF GENOA   (Italy)

^m ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

ⁿ UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLADRIBINE; PROTEIN P53; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN HEAVY CHAIN; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; DRUG RESPONSE; EVENT FREE SURVIVAL; FEMALE; GENE EXPRESSION; HAIRY CELL LEUKEMIA; HUMAN; IGHV GENE; IMMUNOGLOBULIN HEAVY CHAIN GENE; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SPLENOMEGALY; TREATMENT FAILURE; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENETICS; IMMUNOGLOBULIN VARIABLE REGION; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CLADRIBINE; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, HAIRY CELL; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 73949121207     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-03-212449     Document Type: Article

References (49)

1. Lauria F, Forconi F. Towards the pharmacotherapy of hairy cell leukaemia. Expert Opin Pharmacother. 2004;5(7):1523-1533.
2. Piro LD, Ellison DJ, Saven A. The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leuk Lymphoma. 1994;14[suppl 1]:121-125.
3. Robak T, Jamroziak K, Gora-Tybor J, et al. Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood. 2007;109(9):3672-3675.
4. Goodman GR, Burian C, Koziol JA, Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. J Clin Oncol. 2003;21(5):891-896.
5. Dearden C, Else M. Hairy cell leukemia. Curr Oncol Rep. 2006;8(5):337-342.
6. Kreitman RJ, Pastan I. Immunotoxins in the treatment of refractory hairy cell leukemia. Hematol Oncol Clin North Am. 2006;20(5):1137-1151.
7. Stevenson FK, Sahota SS, Ottensmeier CH, Zhu D, Forconi F, Hamblin TJ. The occurrence and significance of V gene mutations in B cell-derived human malignancy. Adv Cancer Res. 2001;83:81-116.
8. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848-1854.
9. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
10. Stevenson FK, Caligaris-Cappio F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood. 2004;103(12):4389-4395.
11. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916.
12. Pettitt AR, Sherrington PD, Cawley JC. The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia. Br J Haematol. 1999;106(4):1049-1051.
13. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993;74(6):957-967.
14. Zenz T, Krober A, Scherer K, et al. Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood. 2008;112(8):3322-3329.
15. Rossi D, Cerri M, Deambrogi C, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemore-fractoriness. Clin Cancer Res. 2009;15(3):995-1004.
16. Kienle D, Krober A, Katzenberger T, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood. 2003;102(8):3003- 3009.
17. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101(12):4975-4981.
18. Forconi F, Sahota SS, Raspadori D, et al. Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch. Blood. 2004;104(10):3312-3317.
19. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC; 2008:441.
20. Maloum K, Magnac C, Azgui Z, et al. VH gene expression in hairy cell leukaemia. Br J Haematol. 1998;101(1):171-178.
21. Thorselius M, Walsh SH, Thunberg U, Hagberg H, Sundstrom C, Rosenquist R. Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. Leuk Res. 2005;29(2):153-158.
22. Forconi F, Sozzi E, Rossi D, et al. Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. Haematologica. 2008;93(5):697-705.
23. Forconi F, Poretti G, Kwee I, et al. High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. Br J Haematol. 2008;141(5):622-630.
24. Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2001.
25. Falini B, Tiacci E, Liso A, et al. Simple diagnostic assay for hairy cell leukaemia by immunocyto-chemical detection of annexin A1 (ANXA1). Lancet. 2004;363(9424):1869-1870.
26. Forconi F, Sahota SS, Raspadori D, Mockridge CI, Lauria F, Stevenson FK. Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. Blood. 2001;98(4):1174-1181.
27. Forconi F, King CA, Sahota SS, Kennaway CK, Russell NH, Stevenson FK. Insight into the potential for DNA idiotypic fusion vaccines designed for patients by analysing xenogeneic anti-idiotypic antibody responses. Immunology. 2002;107(1):39-45.
28. Giudicelli V, Chaume D, Lefranc MP. IMGT/VQUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res. 2004;32:W435-W440.
29. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629.
30. Soussi T, Asselain B, Hamroun D, et al. Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res. 2006;12(1):62-69.
31. Consensus-Resolution. Proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia. 1987;1(4):405.
32. Forconi F, Zaja F, Intermesoli T, et al. Equivalent efficacy and lower toxicity of subcutaneous cladribine at reduced doses (five versus seven consecutive days) in hairy cell leukemia: an interim analysis of the ICGHCL 2004 Protocol by the Italian Cooperative Group on HCL [abstract]. Blood (ASH Annual Meeting Abstracts). 2008;112(11):3174.
33. Cheson BD, Sorensen JM, Vena DA, et al. Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J Clin Oncol. 1998;16(9):3007-3015.
34. Juliusson G, Lenkei R, Liliemark J. Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood. 1994;83(12):3672-3681.
35. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med. 1994;120(9):784-791.
36. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer. 2005;104(11):2442-2448.
37. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood. 2003;102(3):810-813.
38. Zinzani PL, Tani M, Marchi E, et al. Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica. 2004;89(3):309-313.
39. Lauria F, Rondelli D, Raspadori D, Benfenati D, Tura S. Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia. Eur J Haematol. 1994;52(1):16-20.
40. Arons E, Sunshine J, Suntum T, Kreitman RJ. Somatic hypermutation and VH gene usage in hairy cell leukaemia. Br J Haematol. 2006;133(5):504-512.
41. Vasconcelos Y, Davi F, Levy V, et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol. 2003;21(21):3928-3932.
42. Matutes E, Wotherspoon A, Brito-Babapulle V, Catovsky D. The natural history and clinicopathological features of the variant form of hairy cell leukemia. Leukemia. 2001;15(1):184-186.
43. Vallianatou K, Brito-Babapulle V, Matutes E, Atkinson S, Catovsky D. p53 gene deletion and trisomy 12 in hairy cell leukemia and its variant. Leuk Res. 1999;23(11):1041-1045.
44. Thomas DA, O'Brien S, Bueso-Ramos C, et al. Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003;102(12):3906-3911.
45. Ravandi F, Jorgensen JL, O'Brien SM, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood. 2006;107(12):4658-4662.
46. Else M, Osuji N, Forconi F, et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer. 2007;110(10):2240-2247.
47. Forconi F, Toraldo F, Sozzi E, Amato T, Raspadori D, Lauria F. Complete molecular remission induced by concomitant cladribine-rituximab treatment in a case of multi-resistant hairy cell leukemia. Leuk Lymphoma. 2007;48(12):2441- 2443.
48. Else M, Dearden CE, Matutes E, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol. 2009;145(6):733-740.
49. Habermann TM, Andersen JW, Cassileth PA, Bennett JM, Oken MM. Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br J Haematol. 1992;80(4):466-471.